Whole Blood Coagulation Time
"Whole Blood Coagulation Time" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The time required by whole blood to produce a visible clot.
| Descriptor ID |
D014914
|
| MeSH Number(s) |
E01.370.225.625.115.950 E05.200.625.115.950 G09.188.960
|
| Concept/Terms |
Whole Blood Coagulation Time- Whole Blood Coagulation Time
- Blood Coagulation Time, Whole
- Coagulation Time, Whole Blood
- Activated Coagulation Time, Whole Blood
|
Below are MeSH descriptors whose meaning is more general than "Whole Blood Coagulation Time".
Below are MeSH descriptors whose meaning is more specific than "Whole Blood Coagulation Time".
This graph shows the total number of publications written about "Whole Blood Coagulation Time" by people in this website by year, and whether "Whole Blood Coagulation Time" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 1 | 1 | 2 |
| 2010 | 0 | 2 | 2 |
| 2011 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 1 | 0 | 1 |
| 2018 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Whole Blood Coagulation Time" by people in Profiles.
-
Anticoagulation in neonatal ECMO. Semin Perinatol. 2018 Mar; 42(2):122-128.
-
Heparin Reversal After Cardiopulmonary Bypass: Are Point-of-Care Coagulation Tests Interchangeable? J Cardiothorac Vasc Anesth. 2016 Oct; 30(5):1184-9.
-
Anticoagulation monitoring during extracorporeal membrane oxygenation: is anti-factor Xa assay (heparin level) a better test?*. Pediatr Crit Care Med. 2014 Feb; 15(2):178-9.
-
Evaluation of bivalirudin hyper- and hypo-ACT responses in the setting of percutaneous coronary intervention. J Invasive Cardiol. 2013 May; 25(5):250-3.
-
Bleeding risk comparing targeted low-dose heparin with bivalirudin in patients undergoing percutaneous coronary intervention: results from a propensity score-matched analysis of the Evaluation of Drug-Eluting Stents and Ischemic Events (EVENT) registry. Circ Cardiovasc Interv. 2011 Oct 01; 4(5):463-73.
-
Heparin dosing in obese pediatric patients in the cardiac catheterization laboratory. Ann Pharmacother. 2011 Jul; 45(7-8):876-80.
-
Evaluation of heparin assay for coagulation management in newborns undergoing ECMO. Am J Clin Pathol. 2010 Dec; 134(6):950-4.
-
Preoperative heparin therapy causes immune-mediated hypotension upon heparin administration for cardiac surgery. J Cardiothorac Vasc Anesth. 2010 Feb; 24(1):69-72.
-
Monitoring of enoxaparin level using citrated clotting time during percutaneous coronary intervention. J Interv Cardiol. 2004 Oct; 17(5):307-13.
-
Pharmacokinetics and pharmacodynamics of argatroban in combination with a platelet glycoprotein IIB/IIIA receptor antagonist in patients undergoing percutaneous coronary intervention. J Clin Pharmacol. 2004 Sep; 44(9):981-90.